date:Mar 19, 2013
tested the effects of the new agent in the prostate cancer cells.
By reducing two-thirds of the chain, the molecule had a 20 times more potent anti-tumour effect, while retaining the integrity of vitamin Es head group, Chen said. This manipulation enhanced the anti-tumour potency of the molecule by changing its interaction with the cell membrane, so that the head group was more accessible to Akt and PHLPP1.
When mice with tumours created by these two prostate cancer cell lines were injected w